Drug reaction with eosinophilia and systemic symptoms syndrome secondary to acetazolamide associated with markedly elevated procalcitonin.

Szczegóły
Abstrakt

Tytuł:: Drug reaction with eosinophilia and systemic symptoms syndrome secondary to acetazolamide associated with markedly elevated procalcitonin.
Autorzy:: Ali SB; Department of Immunology, Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia .
Schweikert S; Department of Intensive Care Medicine, Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia.
Brusch A; Department of Immunology, Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia.
Źródło:: BMJ case reports [BMJ Case Rep] 2021 Jan 18; Vol. 14 (1). Date of Electronic Publication: 2021 Jan 18.
Typ publikacji:: Case Reports; Journal Article
Język:: English
Imprint Name(s):: Original Publication: London : BMJ Pub. Group
MeSH Terms:: Acetazolamide/*adverse effects
Carbonic Anhydrase Inhibitors/*adverse effects
Drug Hypersensitivity Syndrome/*diagnosis
Procalcitonin/*blood
Aged, 80 and over ; Biomarkers/blood ; Drug Hypersensitivity Syndrome/blood ; Drug Hypersensitivity Syndrome/etiology ; Humans ; Male
References:: J Am Acad Dermatol. 2010 Aug;63(2):219-27. (PMID: 20605253)
J Eur Acad Dermatol Venereol. 2016 Dec;30(12):2077-2084. (PMID: 27225695)
Br J Dermatol. 1997 Oct;137(4):605-8. (PMID: 9390340)
Br J Dermatol. 2014 Apr;170(4):866-73. (PMID: 24329105)
Arch Dermatol. 2010 Dec;146(12):1373-9. (PMID: 20713773)
Joint Bone Spine. 2014 Jan;81(1):15-21. (PMID: 23816504)
JAAD Case Rep. 2018 Oct 13;4(9):959-961. (PMID: 30364766)
Clin Exp Dermatol. 2011 Jan;36(1):6-11. (PMID: 21143513)
Br J Dermatol. 2013 Nov;169(5):1071-80. (PMID: 23855313)
Int Arch Allergy Immunol. 2018;176(1):44-54. (PMID: 29656292)
J Am Acad Dermatol. 2013 May;68(5):693.e1-14; quiz 706-8. (PMID: 23602182)
Am J Med. 2011 Jul;124(7):588-97. (PMID: 21592453)
Chin Med J (Engl). 2017 Apr 20;130(8):943-949. (PMID: 28397724)
Int J Dermatol. 2018 Oct;57(10):1187-1191. (PMID: 30099742)
Br J Dermatol. 2015 Jul;173(1):50-8. (PMID: 25630796)
J Am Acad Dermatol. 2015 Jun;72(6):984-91. (PMID: 25801338)
J Am Acad Dermatol. 2013 May;68(5):709.e1-9; quiz 718-20. (PMID: 23602183)
Int J Mol Sci. 2017 Jun 09;18(6):. (PMID: 28598363)
Contributed Indexing:: Keywords: adult intensive care; immunology; ophthalmology; unwanted effects / adverse reactions
Substance Nomenclature:: 0 (Biomarkers)
0 (Carbonic Anhydrase Inhibitors)
0 (Procalcitonin)
O3FX965V0I (Acetazolamide)
Entry Date(s):: Date Created: 20210119 Date Completed: 20210222 Latest Revision: 20230120
Update Code:: 20240105
PubMed Central ID:: PMC7813420
DOI:: 10.1136/bcr-2020-236966
PMID:: 33462002
: Czasopismo naukowe

Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome is an important cause of multi-organ dysfunction and can mimic other disorders including sepsis. We describe a patient presenting with septic shock and accompanying high procalcitonin. Although initially treated empirically with antibiotics, the emergence of eosinophilia during the admission lead to a revised diagnosis of DRESS syndrome, presumed secondary to acetazolamide. This case highlights the importance of regular clinical assessment and re-evaluation is key in identifying emerging features such as eosinophilia, rash and organ dysfunction, which can secure the diagnosis. Furthermore, the case also highlights that acetazolamide may be a rare cause of DRESS syndrome.
Competing Interests: Competing interests: None declared.
(© BMJ Publishing Group Limited 2021. No commercial re-use. See rights and permissions. Published by BMJ.)

Informacja